Navigation Links
Glenmark’s new molecule to go through trial

Glenmark Pharmaceuticals Ltd today said its newly- found andti-diabetic/anti-obesity molecule will be put into clinical trials by later this year. Mr Glenn Saldanha, Executive Director, Glenmark pharmaceuticals, told newspersons that the company’s R&D team has established ‘proof of concept’ in animals for this molecule.//

The global diabetes market is estimated to be in the region of Rs. 400 crore. The company is scouting for partners to take the molecule into advanced phases of clinical trials. Mr. Saldahna said that the pre-clinical trials for the molecule are expected to be completed in the next six months and then the Phase I clinical studies will be initiated in Europe.

"We are scouting for contract research organisations (CROs) in Europe which will take the moleucle code named - GRC -1087 - through Phase I and probably Phase II A or early Phase II clinical trials. We might be in a position to announce the CRO in the next three months," Mr Saldanha said. The clinical trials will cost around $1 millin.
'"/>




Page: 1

Related medicine news :

1. Poisonous Parkinsons molecule discovered
2. Resistant tumors could be treated with the discovery of a new molecule within cancer cells
3. Ways to counter radiation effects with new molecule discovery
4. Same molecule found in meat, milk, tumors
5. New molecule to treat brain disorders found
6. Cell molecules behind neuro degenerative diseases
7. New anti-aging molecule could be coming up in way
8. So now here might come a memory molecule!!!
9. Lost molecule holds the key to lung cancer
10. THC molecule turns out to a boon for Alzheimer’s patient
11. Sperm washing helps couples – Breakthrough in focu
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Glenmark new molecule through trial

(Date:8/20/2014)... “Have you recently been involved in an auto accident?” asks ... the greater Seattle area. “Are you still feeling the physical ... . , In a recently released article, Dax Jones asks ... use to see if they may qualify for a personal ... will allow an individual to receive medical treatment for their ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers,restraints, challenges, opportunities, current market trends,and strategies ... the estimates and forecasts of the revenue and ...
(Date:8/20/2014)... 20, 2014 Mixberry Media announced today ... websites and create a new source of revenue. , ... by listening to a narration of their favorite news ... and languages. Users can now multitask: read/write email, ... while consuming content. , Mixberry Media’s service ...
(Date:8/20/2014)... Astoria, New York (PRWEB) August 20, 2014 ... to the Global Bureau of Disease, low back pain is ... of the most common reasons for missed work. Americans spend ... of this pain. , Most cases of back pain are ... a mechanical (non-organic) origin. , For example, Pete, a busy ...
(Date:8/19/2014)... 20, 2014 Midtown Dentistry in Houston, Texas, ... office. All patients with cavities, or with old fillings ... fillings that can safely repair and restore teeth. , From ... latest materials, all of which are completely amalgam free. Even ... use by the FDA for adults and children over the ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... , , WASHINGTON , Jan. 13 ... and Bruce A. Mrusek , a resident of Maineville, Ohio , ... Judge Michael R. Barrett in Cincinnati , the Justice Department ... both dentists, wer e i n d ...
... say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... tendon doesn,t appear to be effective, a new study ... plasma (PRP) injections are no better than placebo in ... active. , The study included 54 patients, aged 18 ...
... And rates among boys aged 6-19 still climbing, government study ... news in the war on weight: Obesity in the United ... studies show. , But the rates of obesity remain high, ... category. And, rates of obesity among already heavy 6- to ...
... researchers have found that six essential oils from thyme, ... COX-2 enzyme, in a manner similar to resveratrol, the ... They also identified that the chemical carvacrol was primarily ... appearing in the January issue of Journal of ...
... ... to provide fully integrated topical clinical phase 1 study services for trials in healthy ... , ... January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership ...
... January 21st ... Understand the Latest Developments in VoIP Fax Capabilities, , ... Tigard, Oregon (Vocus) January 13, 2010 -- FaxBack , the ... the Miami Beach Convention Center. , , , , ,At the show, FaxBack (booth ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 2Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 3
(Date:8/19/2014)...  Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... for solid tumor cancers, announced today that the $17.5 ... 2014, has closed.  The three-year notes have a 5% ... of common stock.  The investors also have an option, ... additional 30% of these notes on the same terms. ...
(Date:8/19/2014)... Aug. 19, 2014  Tokyo-based Atonarp Inc. announced ... round led by Walden Riverwood Ventures with participation ... of Atonarp,s Smart Spectrometer technology platform, which will ... has targeted the oil & gas and healthcare ... are excited to partner with Atonarp in pursuing ...
(Date:8/19/2014)... 19, 2014 Avizia, Inc., a leading provider ... closed an equity financing round led by NextGen Angels ... new funding will be used to continue to fuel ... Avizia welcomes Edward Kennedy , CEO and president ... joins Leonard Kurtzman , CFO of newBrandAnalytics, who ...
Breaking Medicine Technology:NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Avizia Closes Funding Round 2
Inquire...
... brings you into the new age of ... offer your patients immediate, long-term results for ... This injectable filler offers superior versatility for ... reconstructive treatments. Long-lasting, Radiesse saves time and ...
... HEMOCHRON Response is a whole ... to be used at the ... easy-to-read screen and data management ... ID options. QC and operator ...
... Revitol Cellulite Cream is a revolutionary ... eliminating inches. Revitol Cellulite Removal Cream permits ... problem areas. With Revitol you can rid ... Just apply the Cellulite Cream to your ...
Medicine Products: